BÜHLMANN Quantum Blue® TDM Assay Citations Archives - Buhlmann Diagnostics Corp

Category: BÜHLMANN Quantum Blue® TDM Assay Citations

Therapeutic Drug Monitoring in Crohn’s Disease Patients

Bodini, G. et al. Therapeutic Drug Monitoring in Crohn's Disease Patients, A Comparison Between Homogenous Mobility Shift Assay and Point of Care Method.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain.  P1750.  Read Citation BÜHLMANN Quantum Blue® IFX is for Research Use Only in the US.  Not for use in diagnostic procedures in the US.
Continue Reading

The New Biosimilar of IFX SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

BÜHLMANN Quantum Blue® IFX Citation: Magro, F., Rocha, C. et al. P229 The new biosimilar of IFX SB2 can be quantified by IFX-optimized therapeutic drug monitoring assays.  Journal of Crohns and Colitis.  2018, Jan. DOI: 10.1093/ecco-jcc/jjx180.356. BÜHLMANN Quantum Blue® IFX is for Research Use Only in the US.  Not for use in diagnostic procedures in the US. Health
Continue Reading

A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® IFX Citation: Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif.  P711 A pilot study using point of care testing for IFX and faecal calprotectin in IBD patients with a secondary loss of response.  Journal of Crohn's and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838. Highlight from
Continue Reading